Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study

Kaji, Hiroshi; Kuroki, Yasuo; Murakawa, Yohko; Funakawa, Itaru; Funasaka, Yoko; Kanda, Fumio; Sugimoto, Toshitsugu

doi:10.1007/s00198-009-1110-z

Cited by 16 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, there was no significant change in the serum level of BAP after glucocorticoid therapy, and previous studies (18)(19)(20) have also found no significant change in the serum BAP level with glucocorticoid therapy. In fact, BAP may not be directly regulated by glucocorticoids because the glucocorticoid response element is not present in the promoter region of the BAP gene (29).…”

Section: Discussionsupporting

confidence: 70%

Efficacy of Vitamin K<sub>2</sub> for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases

et al. 2016

View full text Add to dashboard Cite

Objective Vitamin K2 (menatetrenone) is an effective treatment for patients with postmenopausal osteoporosis. We herein performed a subanalysis of patients with systemic autoimmune diseases undergoing glucocorticoid therapy in our previous prospective study. Methods Sixty patients were categorized into a group with vitamin K2 treatment (n=20, Group A) and a group without vitamin K2 treatment (n=40, Group B). All patients were treated with bisphosphonates. Results Serum levels of osteocalcin and undercarboxylated osteocalcin decreased significantly after the start of glucocorticoid therapy in both groups, while the serum osteocalcin level was significantly higher in Group A than Group B during the third (p=0.0250) and fourth weeks (p=0.0155). The serum level of the N-terminal peptide of type I procollagen, a bone formation marker, decreased during glucocorticoid therapy, but was significantly higher in Group A than Group B during the fourth week (p=0.0400). The bone mineral density and fracture rate showed no significant differences between the two groups. Conclusion Although vitamin K2 improves bone turnover markers in patients with osteoporosis on glucocorticoid therapy, it has no significant effect on the bone mineral density and fracture rate after 1.5 years of treatment.

show abstract

Section: Discussionsupporting

confidence: 70%

Efficacy of Vitamin K<sub>2</sub> for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The notion that bone resorption is tightly linked to glucose homeostasis is clinically important, since most of the drugs used in the treatment of bone disease patients target this aspect of bone remodeling. Specifically, high levels of fasting plasma glucose are measured in osteoporotic women treated with bone resorption inhibitory drugs, and there is a significant and positive correlation between undercarboxylated Ocn and urinary cross-linked N-telopeptides of type I collagen (NTX) [54,55].…”

Section: Glucose Metabolismmentioning

confidence: 99%

The Endocrine Function of Osteocalcin Regulated by Bone Resorption: A Lesson from Reduced and Increased Bone Mass Diseases

Rossi

Battafarano

Pepe

et al. 2019

IJMS

View full text Add to dashboard Cite

Bone is a peculiar tissue subjected to a continuous process of self-renewal essential to assure the integrity of the skeleton and to explicate the endocrine functions. The study of bone diseases characterized by increased or reduced bone mass due to osteoclast alterations has been essential to understand the great role played by osteocalcin in the endocrine functions of the skeleton. The ability of osteoclasts to regulate the decarboxylation of osteocalcin and to control glucose metabolism, male fertility, and cognitive functions was demonstrated by the use of animal models. In this review we described how diseases characterized by defective and increased bone resorption activity, as osteopetrosis and osteoporosis, were essential to understand the involvement of bone tissue in whole body physiology. To translate this knowledge into humans, recently published reports on patients were described, but further studies should be performed to confirm this complex hormonal regulation in humans.

show abstract

“…Such agents have been shown to promote vascular injuries and endothelial damage ( 17 ); however, their role in the pathogenic process of the disease has not been precisely clarified. In the current patient, we believe that the significant increase in the urinary level of NTx should mirror the concomitant disturbance of the bone and calcium metabolism which was induced by the systemic administration of glucocorticoid ( 19 ). Although the patient was no longer dependent on HD at the onset of calciphylaxis, the temporal decline in his renal function might also have predisposed him to the disease through the concurrent mineral disturbance characterized by hyperphosphatemia, which encouraged us to use calcium carbonate as a phosphate binder.…”

Section: Discussionmentioning

confidence: 81%

Minimal Change Nephrotic Syndrome Sequentially Complicated by Acute Kidney Injury and Painful Skin Ulcers due to Calciphylaxis

et al. 2016

View full text Add to dashboard Cite

Calciphylaxis is rare cutaneous manifestation associated with painful skin ulceration and necrosis. It primarily occurs in patients with end-stage chronic kidney disease. In this report, we would like to show our experience with a male patient presenting with minimal change nephrotic syndrome that was sequentially complicated by acute kidney injury and painful ulcerative cutaneous lesions due to calciphylaxis. There seemed to be several contributing factors, including a disturbance of the patient's mineral metabolism and the systemic use of glucocorticoids and warfarin. Various concerns regarding the diagnostic and therapeutic conundrums that were encountered in the present case are also discussed.

show abstract

Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study

Abstract: Alendronate was effective in suppressing bone resorption and subsequent BMD decrease at the lumbar spine in patients with high-dose GC treatment.

Cited by 16 publications

References 33 publications

Efficacy of Vitamin K<sub>2</sub> for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases

Efficacy of Vitamin K<sub>2</sub> for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases

The Endocrine Function of Osteocalcin Regulated by Bone Resorption: A Lesson from Reduced and Increased Bone Mass Diseases

Minimal Change Nephrotic Syndrome Sequentially Complicated by Acute Kidney Injury and Painful Skin Ulcers due to Calciphylaxis

Contact Info

Product

Resources

About